Key result
Induced pluripotent stem cell-based therapy shows accumulating preclinical safety and efficacy data for CNS and cardiovascular repair, despite risks of tumorigenicity and immunogenicity.
Answers are grounded in this paper and cite their sources.
The enthusiasm for producing patient-specific human embryonic stem cells using somatic nuclear transfer has somewhat abated in recent years because of ethical, technical, and political concerns. However, the interest in generating induced pluripotent stem cells (iPSCs), in which pluripotency can be obtained by transcription factor transduction of various somatic cells, has rapidly increased. Human iPSCs are anticipated to open enormous opportunities in the biomedical sciences in terms of cell therapies for regenerative medicine and stem cell modeling of human disease. On the other hand, recent reports have emphasized the pitfalls of iPSC technology, including the potential for genetic and epigenetic abnormalities, tumorigenicity, and immunogenicity of transplanted cells. These constitute serious safety-related concerns for iPSC-based cell therapy. However, preclinical data supporting the safety and efficacy of iPSCs are also accumulating. In this Review, recent achievements and future tasks for safe iPSC-based cell therapy are summarized, using regenerative medicine for repair strategies in the damaged central nervous system (CNS) as a model. Insights on safety and preclinical use of iPSCs in cardiovascular repair model are also discussed.
No takes yet. Share an insight, caveat, or question.
Okano et al. (2013) conducted a review in Central nervous system damage and cardiovascular repair. Induced pluripotent stem cell (iPSC)-based cell therapy was evaluated. Induced pluripotent stem cell-based therapy shows accumulating preclinical safety and efficacy data for CNS and cardiovascular repair, despite risks of tumorigenicity and immunogenicity.
Synapse has enriched 10 related papers. Consider them for comparative context: